[Electron microscope study of lung carcinoid].

N T Raĭklin; E A Smirnova; B E Polotskiĭ; T G Glazkova; B Kh Bebezov; M I Davydov

PubMed · 10598267

[Electron microscope study of lung carcinoid].

N T Raĭklin·E A Smirnova·B E Polotskiĭ·T G Glazkova·B Kh Bebezov·M I Davydov

Abstract

123 lung carcinoids were studied, 32 of them electron-microscopically. Ultrastructural features were evaluated with the use of multivariate analysis. The most informative ultrastructural features were the following: correlation between differentiated and undifferentiated cells, the number of cytoplasm organoids including endocrine granules, degree of nuclei polymorphism and their size, specialized contacts, mitoses. Up to 18% of carcinoids, on the average, need ultrastructural verification of the anaplasia degree, this percentage increasing to 27.2% in atypical carcinoids. The above ultrastructural criteria allow to specify malignant potential of carcinoids, facilitate differential diagnosis and make their prognosis.

Explore related subjects

Carcinoid Tumor Female Humans Lung Neoplasms Male Microscopy, Electron Prognosis Survival Analysis English Abstract Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

N T Raĭklin, E A Smirnova, B E Polotskiĭ, T G Glazkova, B Kh Bebezov, M I Davydov. [Electron microscope study of lung carcinoid].. https://pubmed.ncbi.nlm.nih.gov/10598267/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Immunohistochemical analysis of sox9 in ovarian Sertoli cell tumors and other tumors in the differential diagnosis.

The distinction of ovarian Sertoli cell tumor from other tumors in the histological differential diagnosis, particularly endometrioid carcinoma and carcinoid tumor, may be difficult. Many immunohistochemical markers have been studied for this differential diagnosis, but currently available markers are neither 100% sensitive nor specific. Sox9 is a transcription factor involved in Sertoli cell differentiation in the testis. The role that this molecule plays in the pathogenesis of ovarian Sertoli cell tumors and the potential use as an immunohistochemical marker for differential diagnosis have not been investigated. Immunohistochemical staining for Sox9 was performed in 152 ovarian tumors: pure Sertoli cell tumor (n = 36), endometrioid borderline tumor (n = 38), well-differentiated endometrioid carcinoma (n = 26), sertoliform endometrioid carcinoma (n = 13), and carcinoid tumor (n = 39). Nuclear expression was considered positive. Extent and intensity of staining were semiquantitatively scored. In addition, immunohistochemical composite scores in positive cases (ranging from 1 to 12) were calculated based on the extent score multiplied by the intensity score. Sox9 was expressed in 44% of Sertoli cell tumors, 55% of endometrioid borderline tumors, 65% of well-differentiated endometrioid carcinomas, 39% of sertoliform endometrioid carcinomas, and 10% of carcinoid tumors. The mean Sox9 immunohistochemical composite scores in positive cases were 6.3 for Sertoli cell tumor, 5.3 for endometrioid borderline tumor, 8.0 for well-differentiated endometrioid carcinoma, 2.8 for sertoliform endometrioid carcinoma, and 6.8 for carcinoid tumor. The differences in the mean Sox9 composite scores between Sertoli cell tumor and the other tumor categories were not statistically significant (p values ranged from 0.092 to 0.523). We conclude that Sox9 is variably expressed in ovarian Sertoli cell tumor and other tumors that are in the differential diagnosis and, thus, is not helpful for immunohistochemical distinction. Understanding the role of Sox9 in the pathogenesis of ovarian Sertoli cell tumor requires further study.

Carcinoid Tumor↗

PubMed2007

Large bowel carcinoid tumors.

PURPOSE OF REVIEW: Gastrointestinal carcinoids comprise 90% of all carcinoid tumors and all carcinoids have malignant potential. This review focuses on the morphology, prognosis, detection and treatment for appendiceal, colonic and rectal carcinoids. RECENT FINDINGS: Computed tomography exists as an initial examination for the primary carcinoid tumor as well as for metastases. There have, however, been recent developments of newer and more accurate modalities. Octreotide scanning has a sensitivity of primary tumor detection of 90%; additionally, I- or I-meta-iodobenzylguanidine scanning and tracer-specific positron emission tomographic scans have demonstrated encouraging results. Further advancements in treatment with tumor-targeted therapy and biochemical evaluation of carcinoids have shown promise. SUMMARY: The recent progress with scintigraphic and radiologic modalities has provided better means for diagnosis of primary and metastatic carcinoid tumors. These newly discovered diagnostic modalities have been more encouraging than the recent treatment approaches that have been studied with regard to metastatic carcinoids. While surgery remains the mainstay of treatment of nonmetastatic carcinoid, there have been studies for various medical treatments of metastatic disease. Unfortunately, there have been disappointing results with regard to improvement of tumor response and patient survival, but a foundation has been established for future trials employing alternative agents and exploration of combination therapies.

Carcinoid Tumor↗

PubMed2007

Epidemiology of non-gastroenteropancreatic (neuro)endocrine tumours.

The widespread availability and reliability of immunohistochemical techniques in the last three decades have allowed researchers to identify cells with common neuroendocrine markers in virtually every organ. As a whole, these neuroendocrine cells form the so-called diffuse neuroendocrine system. Tumours arising from the cells of the diffuse neuroendocrine system are defined as (neuro)endocrine tumours (NETs). NETs have been increasingly described in recent years. However, despite the increase in the number of published papers focused on NET, we still lack adequate epidemiological data, particularly for non-gastroenteropancreatic (GEP) NETs. Furthermore, the real incidence of neuroendocrine differentiation for most sites is not completely known and is probably underestimated. As a consequence, data on the clinical features of many NET subgroups are not well known or confusing. For all of these reasons, we have attempted to evaluate the epidemiology of non-GEP NETs, reviewing the limited data available in the literature.

Carcinoid Tumor↗